ANI Pharma (ANIP) Approves $25M Common Stock Buyback Plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- S&P 500 ends down after Trump says Iran deal is 'over'
- Oil settles at multi-week high as US-Iran truce buckles under fresh hostilities
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- GameStop stockholders approve share count increase to 2.5 billion
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
ANI Pharmaceuticals Announces Board Authorization of Stock Repurchase Program
October 5, 2015 8:00 AM EDTBAUDETTE, Minn., Oct. 5, 2015 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP)  announced today that its Board of Directors has authorized a stock repurchase program under which the Company may repurchase up to $25 million of shares of the Company's common stock. ANI expects to fund the stock repurchase program through cash on hand. Â
The authorization allows for repurchases to be conducted through open market or through privately negotiated transactions through December 31, 2016. The number of shares repurchased and the timing of repurchases will depend on a number of factors, including, but not... More
